Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,842,850
  • Shares Outstanding, K 576,857
  • Annual Sales, $ 2,378 M
  • Annual Income, $ 770,950 K
  • EBIT $ 1,560 M
  • EBITDA $ 1,592 M
  • 60-Month Beta 0.39
  • Price/Sales 11.76
  • Price/Cash Flow 10.15
  • Price/Book 2.88

Options Overview Details

View History
  • Implied Volatility 35.88% (+1.10%)
  • Historical Volatility 22.13%
  • IV Percentile 39%
  • IV Rank 29.75%
  • IV High 75.80% on 01/14/26
  • IV Low 18.96% on 05/21/25
  • Expected Move (DTE 25) 3.29 (6.67%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 18
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 8,978
  • Open Int (30-Day) 14,440
  • Expected Range 46.01 to 52.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.22
  • Number of Estimates 3
  • High Estimate $1.30
  • Low Estimate $1.17
  • Prior Year $1.06
  • Growth Rate Est. (year over year) +15.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.04 +9.46%
on 03/23/26
50.08 -1.55%
on 04/20/26
+3.94 (+8.69%)
since 03/20/26
3-Month
39.02 +26.35%
on 01/21/26
50.08 -1.55%
on 04/20/26
+10.21 (+26.12%)
since 01/20/26
52-Week
31.58 +56.11%
on 04/24/25
50.08 -1.55%
on 04/20/26
+16.70 (+51.23%)
since 04/17/25

Most Recent Stories

More News
Royalty Pharma Declares Second Quarter 2026 Dividend

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary...

RPRX : 49.30 (-1.40%)
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial...

RPRX : 49.30 (-1.40%)
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

CORT : 46.34 (+0.39%)
RPRX : 49.30 (-1.40%)
SYK : 338.34 (-1.45%)
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest

Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest

RPRX : 49.30 (-1.40%)
1 Value Stock for Long-Term Investors and 2 Facing Challenges

1 Value Stock for Long-Term Investors and 2 Facing Challenges

RPRX : 49.30 (-1.40%)
SNAP : 6.00 (-0.50%)
DIS : 106.30 (+0.01%)
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm

1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm

RPRX : 49.30 (-1.40%)
CHRD : 127.06 (+2.82%)
DOCU : 47.71 (+4.31%)
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million...

RPRX : 49.30 (-1.40%)
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?

RPRX : 49.30 (-1.40%)
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead...

RPRX : 49.30 (-1.40%)
Royalty Pharma Announces Expansion of Leadership Team

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering...

RPRX : 49.30 (-1.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 50.66
2nd Resistance Point 50.37
1st Resistance Point 49.83
Last Price 49.30
1st Support Level 49.01
2nd Support Level 48.72
3rd Support Level 48.18

See More

52-Week High 50.08
Last Price 49.30
Fibonacci 61.8% 43.01
Fibonacci 50% 40.83
Fibonacci 38.2% 38.65
52-Week Low 31.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.